Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. CS (NQ: MRUS )

51.78 +1.92 (+3.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 257,050
Open 50.06
Bid (Size) 50.10 (1)
Ask (Size) 53.25 (1)
Prev. Close 49.86
Today's Range 49.85 - 51.86
52wk Range 19.80 - 61.61
Shares Outstanding 46,530,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation 
From Merus N.V.
Via GlobeNewswire

Performance

YTD
+80.92%
+80.92%
1 Month
+2.80%
+2.80%
3 Month
-7.05%
-7.05%
6 Month
+17.66%
+17.66%
1 Year
+136.98%
+136.98%

More News

Read More
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
From Merus N.V.
Via GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
From Merus N.V.
Via GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Announces Pricing of Upsized Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Crude Oil Rises 1%; Verastem Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Via Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
Via Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
Via Investor's Business Daily
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
From Merus N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.